Advertisement

Endocrine

, Volume 56, Issue 2, pp 245–261 | Cite as

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)

  • Luisella Cianferotti
  • Francesco Bertoldo
  • Heike A. Bischoff-Ferrari
  • Olivier Bruyere
  • Cyrus Cooper
  • Maurizio Cutolo
  • John A. Kanis
  • Jean-Marc Kaufman
  • Jean-Yves Reginster
  • Rene Rizzoli
  • Maria Luisa BrandiEmail author
Position statement/Guideline

Abstract

Introduction

Optimal vitamin D status promotes skeletal health and is recommended with specific treatment in individuals at high risk for fragility fractures. A growing body of literature has provided indirect and some direct evidence for possible extraskeletal vitamin D-related effects.

Purpose and Methods

Members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis have reviewed the main evidence for possible proven benefits of vitamin D supplementation in adults at risk of or with overt chronic extra-skeletal diseases, providing recommendations and guidelines for future studies in this field.

Results and conclusions

Robust mechanistic evidence is available from in vitro studies and in vivo animal studies, usually employing cholecalciferol, calcidiol or calcitriol in pharmacologic rather than physiologic doses. Although many cross-sectional and prospective association studies in humans have shown that low 25-hydroxyvitamin D levels (i.e., <50 nmol/L) are consistently associated with chronic diseases, further strengthened by a dose-response relationship, several meta-analyses of clinical trials have shown contradictory results. Overall, large randomized controlled trials with sufficient doses of vitamin D are missing, and available small to moderate-size trials often included people with baseline levels of serum 25-hydroxyvitamin D levels >50 nmol/L, did not simultaneously assess multiple outcomes, and did not report overall safety (e.g., falls). Thus, no recommendations can be made to date for the use of vitamin D supplementation in general, parental compounds, or non-hypercalcemic vitamin D analogs in the prevention and treatment of extra-skeletal chronic diseases. Moreover, attainment of serum 25-hydroxyvitamin D levels well above the threshold desired for bone health cannot be recommended based on current evidence, since safety has yet to be confirmed. Finally, the promising findings from mechanistic studies, large cohort studies, and small clinical trials obtained for autoimmune diseases (including type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus), cardiovascular disorders, and overall reduction in mortality require further confirmation.

Keywords

Cholecalciferol Cancer Diabetes Mortality Cardiovascular diseases Autoimmune diseases 

Notes

Acknowledgements

This paper was derived from a Working Group meeting supported by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Conflict of interest

H.A.B.F. contributed as invitated speaker and on advisory boards for Roche, Pfizer, Sanofi, DSM Nutritional Products, Nestlé and WILD. She received investigator initiated and independent funding from DSM Nutritional Products, Roche Diagnostics, Pfizer and Nestlé. O.B. has disclosed that he has received grant support from IBSA, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, and Theramex; lecture fees from IBSA, Rottapharm, Meda, Servier, and SMB. C.C. has received consultancy fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. J.A.K. reports grants from Amgen, grants from Lilly, non-financial support from Medimaps, non-financial support from Asahi, grants from Radius Health, other from AgNovos, outside the submitted work; and Dr Kanis is the architect of FRAX but has no financial interest. J.M.K. has received consultancy fees rom Amgen and Eli Lilly. J-Y.R. has received consultancy fees or paid advisory boards from Servier, IBSA-Genevrier, UCB, Asahi, Radius Health, Meda, Pierre Fabre; he has received lecture fees from Merck Sharp & Dohme, IBSA-Genevrier, Servier, Danone, Pharmevo Cniel, Meda, Dairy Research Council (DRC); he has received grant support from Merck Sharp & Dohme, Amgen, Lilly, Sevier Pfizer, Danone, Meda, Cniel, IBSA-Genevrier. R.R.: Speaker Bureau of Companies in the Mineral Metabolism Field (Amgen, Danone, Takeda); member of Scientific Advisory Boards of Amgen, Danone, Labatec, Nestlé, Radius Health. M.L.B. has received consultancy fees and grant support from: Alexion, Abiogen, Amgen, Eli Lilly and Shire. The remaining authors declare that they have no conflict of interest.

References

  1. 1.
    G.-H. Fuleihan, R. Bouillon, B. Clarke, M. Chakhtoura, C. Cooper, M. McClung, R.J. Singh, Serum 25-hydroxyvitamin D Levels: variability, knowledge gaps, and the concept of a desirable range. J. Bone. Miner. Res. 30, 1119–1133 (2015)CrossRefGoogle Scholar
  2. 2.
    H.A. Bischoff-Ferrari, A. Shao, B. Dawson-Hughes., J. Hathcock, E. Giovannucci, W.C. Willett, Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 21, 1121–1132 (2010)PubMedCrossRefGoogle Scholar
  3. 3.
    M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 97, 1153–1158 (2012)PubMedCrossRefGoogle Scholar
  4. 4.
    C.J. Rosen, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, J.E. Manson, S.T. Mayne, A.C. Ross, S.A. Shapses, C.L. Taylor, IOM committee members respond to Endocrine Society vitamin D guideline. J. Clin. Endocrinol. Metab. 97, 1146–1152 (2012)PubMedCrossRefGoogle Scholar
  5. 5.
    R. Rizzoli, S. Boonen, M.L. Brandi, O. Bruyère, C. Cooper, J.A. Kanis, J.M. Kaufman, J.D. Ringe, G. Weryha, J.Y. Reginster, Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr. Med. Res. Opin. 29, 305–313 (2013)PubMedCrossRefGoogle Scholar
  6. 6.
    H.A. Bischoff-Ferrari, W.C. Willett, E.J. Orav, E.J. Orav, P. Lips, P.J. Meunier, R.A. Lyons, L. Flicker, J. Wark, R.D. Jackson, J.A. Cauley, H.E. Meyer, M. Pfeifer, K.M. Sanders, H.B. Stähelin, R. Theiler, B. Dawson-Hughes, A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367, 40–49 (2012)PubMedCrossRefGoogle Scholar
  7. 7.
    H.A. Bischoff-Ferrari, B. Dawson-Hughes, E.J. Orav, H.B. Staehelin, O.W. Meyer, R. Theiler, W. Dick, W.C. Willett, A. Egli, Monthly high-dose Vitamin D Treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern. Med 176, 175–183 (2016)PubMedCrossRefGoogle Scholar
  8. 8.
    N.M. van Schoor, P. Lips, Worldwide vitamin D status. Best. Pract. Res. Clin. Endocrinol. Metab. 25, 671–680 (2011)PubMedCrossRefGoogle Scholar
  9. 9.
    K.D. Cashman, K.G. Dowling, Z. Škrabáková, M. Gonzalez-Gross, J. Valtueña, S. De Henauw, L. Moreno, C.T. Damsgaard, K.F. Michaelsen, C. Mølgaard, R. Jorde, G. Grimnes, G. Moschonis, C. Mavrogianni, Y. Manios, M. Thamm, G.B. Mensink, M. Rabenberg, M.A. Busch, L. Cox, S. Meadows, G. Goldberg, A. Prentice, J.M. Dekker, G. Nijpels, S. Pilz, K.M. Swart, N.M. van Schoor, P. Lips, G. Eiriksdottir, V. Gudnason, M.F. Cotch, S. Koskinen, C. Lamberg-Allardt, R.A. Durazo-Arvizu, C.T. Sempos, M. Kiely, Vitamin D deficiency in Europe: pandemic? Am. J. Clin. Nutr. 103, 1033–1044 (2016)PubMedCrossRefGoogle Scholar
  10. 10.
    J.C. Gallagher, A. Sai, T. Templin 2nd, L. Smith, Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann. Intern. Med. 156, 425–437 (2012)PubMedCrossRefGoogle Scholar
  11. 11.
  12. 12.
    S.J. Wimalawansa, Non-musculoskeletal benefits of Vitamin D. J. Steroid Biochem. Mol. Biol. pii: S0960-0760(16)30252-7. doi:  10.1016/j.jsbmb.2016.09.016. [Epub ahead of print] (2016)
  13. 13.
    S. Christakos, P. Dhawan, A. Verstuyf, L. Verlinden, G. Carmeliet, Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev. 96, 365–408 (2016)PubMedCrossRefGoogle Scholar
  14. 14.
    E. Theodoratou, I. Tzoulaki, L. Zgaga, J.P. Ioannidis, Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348, g2035 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    H.A. Bischoff-Ferrari, E.J. Orav, W.C. Willett, B. Dawson-Hughes, The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. Lancet Diabetes Endocrinol 2, 363–364 (2014)PubMedCrossRefGoogle Scholar
  16. 16.
    C.J. Rosen, J.S. Adams, D.D. Bikle, D.M. Black, M.B. Demay, J.E. Manson, M.H. Murad, C.S. Kovacs, The nonskeletal effects of vitamin D: an endocrine society scientific statement. Endocr. Rev. 33, 456–492 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    L. Cianferotti, S. Parri, G. Gronchi, C. Rizzuti, C. Fossi, D.M. Black, M.L. Brandi, Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset. Osteoporos. Int. 26, 2695–2702 (2015)PubMedCrossRefGoogle Scholar
  18. 18.
    S.T. Sollid, M.Y. Hutchinson, V. Berg, O.M. Fuskevåg, Y. Figenschau, P.M. Thorsby, R. Jorde, Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D. Eur. J. Endocrinol. 174, 445–452 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    L. Cianferotti, C. Marcocci, Subclinical vitamin D deficiency. Best. Pract. Res. Clin. Endocrinol. Metab. 26, 523–537 (2012)PubMedCrossRefGoogle Scholar
  20. 20.
    A. Hossein-nezhad, A. Spira, M.F. Holick, Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One 8(3), e58725 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    D.D. Bikle, Extraskeletal actions of vitamin D. Ann. N. Y. Acad. Sci. 1376, 29–52 (2016)PubMedCrossRefGoogle Scholar
  22. 22.
    R. Bouillon, H. Bischoff-Ferrari, W. Willett, Vitamin D and health: perspectives from mice and man. J. Bone Miner. Res. 23, 974–979 (2008)PubMedCrossRefGoogle Scholar
  23. 23.
    T. Suda, R. Masuyama, R. Bouillon, G. Carmeliet, Physiological functions of vitamin D: what we have learned from global and conditional VDRknockout mouse studies. Curr. Opin. Pharmacol. 22, 87–99 (2015)PubMedCrossRefGoogle Scholar
  24. 24.
    L. Cianferotti, M. Cox, K. Skorija, M.B. Demay, Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl Acad. Sci. USA 104, 9428–9433 (2007)PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    S. Chen, C.S. Law, C.L. Grigsby, K. Olsen, T.T. Hong, Y. Zhang, Y. Yeghiazarians, D.G. Gardner, Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124, 1838–1847 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    C. Mathieu, E. Van Etten, C. Gysemans, B. Decallonne, S. Kato, J. Laureys, J. Depovere, D. Valckx, A. Verstuyf, R. Bouillon, In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J. Bone Miner. Res. 16, 2057–2065 (2001)PubMedCrossRefGoogle Scholar
  27. 27.
    L. Ceglia, S.S. Harris, Vitamin D and its role in skeletal muscle. Calcif. Tissue Int. 92, 151–162 (2013)PubMedCrossRefGoogle Scholar
  28. 28.
    L. Song, G. Papaioannou, H. Zhao, H.F. Luderer, C. Miller, C. Dall’Osso, R.M. Nazarian, A.J. Wagers, M.B. Demay, The vitamin D receptor regulates tissue resident macrophage response to injury. Endocrinology 157, 4066–4075 (2016)PubMedCrossRefGoogle Scholar
  29. 29.
    D.D. Bikle, Y. Oda, C.L. Tu, Y. Jiang, Novel mechanisms for the vitamin D receptor (VDR) in the skin and in skin cancer. J. Steroid Biochem. Mol. Biol. 148, 47–51 (2015)PubMedCrossRefGoogle Scholar
  30. 30.
    Elliott, P. Sodium, potassium, body mass, alcohol and blood pressure: the intersalt study. the intersalt co-operative research group. J. Hypertens. 6, S584–S586 (2012)Google Scholar
  31. 31.
    F. Boulay, F. Berthier, O. Sisteron, Y. Gendreike, P. Gibelin, Seasonal variation in chronic heart failure hospitalizations and mortality in France. Circulation 100, 280–286 (1999)PubMedCrossRefGoogle Scholar
  32. 32.
    P.E. Norman, J.T. Powell, Vitamin D and cardiovascular disease. Circ. Res. 114, 379–393 (2014)PubMedCrossRefGoogle Scholar
  33. 33.
    S. Pilz, N. Verheyen, M.R. Grübler, A. Tomaschitz, W. März, Vitamin D and cardiovascular disease prevention. Nat. Rev. Cardiol. 13, 404–417 (2016)PubMedCrossRefGoogle Scholar
  34. 34.
    A. Vaidya, J.S. Williams, The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 61, 450–458 (2012)PubMedCrossRefGoogle Scholar
  35. 35.
    J.P. Forman, E. Giovannucci, M.D. Holmes, H.A. Bischoff-Ferrari, S.S. Tworoger, W.C. Willett, G.C. Curhan, Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063–1069 (2007)PubMedCrossRefGoogle Scholar
  36. 36.
    J.P. Forman, H.A. Bischoff-Ferrari, W.C. Willett, M.J. Stampfer, G.C. Curhan, Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 46, 676–682 (2005)PubMedCrossRefGoogle Scholar
  37. 37.
    E. Giovannucci, Y. Liu, B.W. Hollis, E.B. Rimm, 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168, 1174–1180 (2008)PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    H. Dobnig, S. Pilz, H. Scharnagl, W. Renner, U. Seelhorst, B. Wellnitz, J. Kinkeldei, B.O. Boehm, G. Weihrauch, W. Maerz, Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340–1349 (2008)PubMedCrossRefGoogle Scholar
  39. 39.
    S. Pilz, H. Dobnig, G. Nijpels, R.J. Heine, C.D. Stehouwer, M.B. Snijder, R.M. van Dam, J.M. Dekker, Vitamin D and mortality in older men and women. Clin. Endocrinol. 71, 666–672 (2009)CrossRefGoogle Scholar
  40. 40.
    H. Johansson, A. Odén, J. Kanis, E. McCloskey, M. Lorentzon, Ö. Ljunggren, M.K. Karlsson, P.M. Thorsby, Å. Tivesten, E. Barrett-Connor, C. Ohlsson, D. Mellström, Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos. Int. 23, 991–999 (2012)PubMedCrossRefGoogle Scholar
  41. 41.
    J. El Hilali, E.J. de Koning, A.J. van Ballegooijen, P. Lips, E. Sohl, H.W. van Marwijk, M. Visser, N.M. van Schoor, Vitamin D, PTH and the risk of overall and disease-specific mortality: results of the longitudinal aging study Amsterdam. J. Steroid Biochem. Mol. Biol. 164, 386–394 (2015)Google Scholar
  42. 42.
    M.L. Melamed, P. Muntner, E.D. Michos, J. Uribarri, C. Weber, J. Sharma, P. Raggi, Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler. Thromb. Vasc. Biol. 28, 1179–1185 (2008)PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    K.S. Vimaleswaran, A. Cavadino, D.J. Berry; LifeLines Cohort Study investigators; International Consortium for Blood Pressure (ICBP); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium; Global Blood Pressure Genetics (Global BPGen) consortium., Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelianrandomisation study. Lancet Diabetes Endocrinol. 2, 719–729 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    O. Trummer, S. Pilz, M.M. Hoffmann, B.R. Winkelmann, B.O. Boehm, W. März, T.R. Pieber, B. Obermayer-Pietsch, W. Renner, Vitamin D and mortality: a Mendelian randomization study. Clin. Chem. 59, 793–797 (2013)PubMedCrossRefGoogle Scholar
  45. 45.
    R. Krause, M. Bühring, W. Hopfenmüller, M.F. Holick, A.M. Sharma, Ultraviolet B and blood pressure. Lancet 352, 709–710 (1998)PubMedCrossRefGoogle Scholar
  46. 46.
    M. Pfeifer, B. Begerow, H.W. Minne, D. Nachtigall, C. Hansen, Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86, 1633–1637 (2001)PubMedGoogle Scholar
  47. 47.
    H.A. Bischoff-Ferrari, B. Dawson-Hughes, E. Stöcklin, E. Sidelnikov, W.C. Willett, J.O. Edel, H.B. Stähelin, S. Wolfram, A. Jetter, J. Schwager, J. Henschkowski, A. von Eckardstein, A. Egli, Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J. Bone Miner. Res. 27, 160–169 (2012)PubMedCrossRefGoogle Scholar
  48. 48.
    S. Pilz, M. Gaksch, K. Kienreich, M. Grübler, N. Verheyen, A. Fahrleitner-Pammer, G. Treiber, C. Drechsler, B. Ó Hartaigh, B. Obermayer-Pietsch, V. Schwetz, F. Aberer, J. Mader, H. Scharnagl, A. Meinitzer, E. Lerchbaum, J.M. Dekker, A. Zittermann, W. März, A. Tomaschitz, Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension 65, 1195–1201 (2015)PubMedCrossRefGoogle Scholar
  49. 49.
    M.R. Grübler, M. Gaksch, K. Kienreich, N. Verheyen, J. Schmid, B.W. Ó Hartaigh, G. Richtig, H. Scharnagl, A. Meinitzer, B. Pieske, A. Fahrleitner-Pammer, W. März, A. Tomaschitz, S. Pilz, Effects of vitamin D supplementation on plasma aldosterone and renin—a randomized placebo-controlled trial. J. Clin. Hypertens. 18, 608–613 (2016)CrossRefGoogle Scholar
  50. 50.
    M.D. Witham, M.A. Nadir, A.D. Struthers, Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J. Hypertens. 27, 1948–1954 (2009)PubMedCrossRefGoogle Scholar
  51. 51.
    S.H. Wu, S.C. Ho, L. Zhong, Effects of vitamin D supplementation on blood pressure. South. Med. J. 103, 729–737 (2010)PubMedCrossRefGoogle Scholar
  52. 52.
    A.G. Pittas, M. Chung, T. Trikalinos, J. Mitri, M. Brendel, K. Patel, A.H. Lichtenstein, J. Lau, E.M. Balk, Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152, 307–314 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    M.B. Elamin, N.O. Abu Elnour, K.B. Elamin, M.M. Fatourechi, A.A. Alkatib, J.P. Almandoz, H. Liu, M.A. Lane, R.J. Mullan, A. Hazem, P.J. Erwin, D.D. Hensrud, M.H. Murad, V.M. Montori, Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 1931–1942 (2011)PubMedCrossRefGoogle Scholar
  54. 54.
    L.A. Beveridge, A.D. Struthers, F. Khan, R. Jorde, R. Scragg, H.M. Macdonald, J.A. Alvarez, R.S. Boxer, A. Dalbeni, A.D. Gepner, N.M. Isbel, T. Larsen, J. Nagpal., W.G. Petchey, H. Stricker, F. Strobel., V. Tangpricha, L. Toxqui, M.P. Vaquero, L. Wamberg, A. Zittermann, M.D. Witham; D-PRESSURE Collaboration. Effect of Vitamin D Supplementation on Blood Pressure, A systematic review and meta-analysis incorporating individual patient data. JAMA Intern. Med 175, 745–754 (2015)PubMedCrossRefGoogle Scholar
  55. 55.
    G. Bjelakovic, L.L. Gluud, D. Nikolova, K. Whitfield, J. Wetterslev, R.G. Simonetti, M. Bjelakovic, C. Gluud: Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. (1):CD007470. doi: 10.1002/14651858.CD007470.pub3 (2014)
  56. 56.
    M.J. Bolland, A. Grey, G.D. Gamble, I.R. Reid, The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2, 307–320 (2014)PubMedCrossRefGoogle Scholar
  57. 57.
    J.A. Ford, G.S. MacLennan, A. Avenell, M. Bolland, A. Grey, M. Witham; Record Trial Group., Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am. J. Clin. Nutr. 100, 746–755 (2014)PubMedCrossRefGoogle Scholar
  58. 58.
    M. Visser, D.J. Deeg, M.T. Puts, J.C. Seidell, P. Lips, Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am. J. Clin. Nutr. 84, 616–622 (2006)PubMedGoogle Scholar
  59. 59.
    A.A. Ginde, R. Scragg, R.S. Schwartz, C.A. Camargo Jr., Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. Adults. J. Am. Geriatr. Soc. 57, 1595–1603 (2009)PubMedCrossRefGoogle Scholar
  60. 60.
    M.L. Melamed, E.D. Michos, W. Post, B. Astor, 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168, 1629–1637 (2008)PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    A. Zittermann, S.S. Schleithoff, S. Frisch, C. Götting, J. Kuhn, H. Koertke, K. Kleesiek, G. Tenderich, R. Koerfer, Circulating calcitriol concentrations and total mortality. Clin. Chem. 55, 1163–1170 (2009)PubMedCrossRefGoogle Scholar
  62. 62.
    R. Chowdhury, S. Kunutsor, A. Vitezova, C. Oliver-Williams, S. Chowdhury, J.C. Kiefte-de-Jong, H. Khan, C.P. Baena, D. Prabhakaran, M.B. Hoshen, B.S. Feldman, A. Pan, L. Johnson, F. Crowe, F.B. Hu, O.H. Franco, Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 348, g1903 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jorgensen, B.H. Thuesen, M. Fenger, A. Linnerberg, Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 43, 618–625 (2013)PubMedCrossRefGoogle Scholar
  64. 64.
    K. Michaëlsson, J.A. Baron, G. Snellman, R. Gedeborg, L. Byberg, J. Sundström, L. Berglund, J. Arnlöv, P. Hellman, R. Blomhoff, A. Wolk, H. Garmo, L. Holmberg, H. Melhus, Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am. J. Clin. Nutr. 92, 841–848 (2010)PubMedCrossRefGoogle Scholar
  65. 65.
    S. Pilz, M. Grübler, M. Gaksch, V. Schwetz, C. Trummer, B.Ó. Hartaigh, N. Verheyen, A. Tomaschitz, W. März, Vitamin D and mortality. Anticancer Res. 36, 1379–1387 (2016)PubMedGoogle Scholar
  66. 66.
    A. Aleksova, A.P. Beltrami, R. Belfiore, G. Barbati, M. Di Nucci, S. Scapol, V. De Paris, C. Carriere, G. Sinagra, U-shaped relationship between vitamin D levels and long-term outcome in large cohort of survivors of acute myocardial infarction. Int. J. Cardiol. 223, 962–966 (2016)PubMedCrossRefGoogle Scholar
  67. 67.
    W.B. Grant, S.N. Karras, H.A. Bischoff-Ferrari, C. Annweiler, B.J. Boucher, A. Juzeniene, C.F. Garland, M.F. Holick, Do studies reporting ‘U’-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects? Dermato-Endocrinology 8, e1187349 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    J.E. Manson, S.S. Bassuk, I.M. Lee, N.R. Cook, M.A. Albert, D. Gordon, E. Zaharris, J.G. Macfadyen, E. Danielson, J. Lin, S.M. Zhang, J.E. Buring, The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials 33, 159–171 (2012)PubMedCrossRefGoogle Scholar
  69. 69.
    Zurich EC-Uo. http://do-health.eu/wordpress/. Accessed 12 Dec 2016
  70. 70.
    J. Mitri, A.G. Pittas, Vitamin D and diabetes. Endocrinol. Metab. Clin. N. Am. 43, 205–232 (2014)CrossRefGoogle Scholar
  71. 71.
    A.W. Norman, J.B. Frankel, A.M. Heldt, G.M. Grodsky, Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209, 823–825 (1980)PubMedCrossRefGoogle Scholar
  72. 72.
    M.C. d’Emden, M. Dunlop, R.G. Larkins, J.D. Wark, The in vitro effect of 1 alpha,25-dihydroxyvitamin D3 on insulin production by neonatal rat islets. Biochem. Biophys. Res. Commun. 164, 413–418 (1989)PubMedCrossRefGoogle Scholar
  73. 73.
    I. Zostautiene, R. Jorde, H. Schirmer, E.B. Mathiesen, I. Njølstad, M.L. Løchen, T. Wilsgaard, R.M. Joakimsen, E. Kamycheva, Genetic variations in the Vitamin D receptor predict type 2 diabetes and myocardial infarction in a community-based population: the Tromsø study. PLoS. One 10(12), e0145359 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    R. Scragg, M. Sowers, C. Bell; Third National Health and Nutrition Examination Survey., Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third National Health and Nutrition Examination Survey. Diabetes. Care 27, 2813–2818 (2004)PubMedCrossRefGoogle Scholar
  75. 75.
    A.G. Pittas, B. Dawson-Hughes, T. Li, R.M. Van Dam, W.C. Willett, J.E. Manson, F.B. Hu, Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29, 650–656 (2006)PubMedCrossRefGoogle Scholar
  76. 76.
    M. Herrmann, D.R. Sullivan, A.S. Veillard, T. McCorquodale, I.R. Straub, R. Scott, M. Laakso, D. Topliss, A.J. Jenkins, S. Blankenberg, A. Burton, A.C. Keech; Field Study Investigators., Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 38, 521–528 (2015)PubMedCrossRefGoogle Scholar
  77. 77.
    Y. Song, L. Wang, A.G. Pittas, L.C. Del Gobbo, C. Zhang, J.E. Manson, F.B. Hu, Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 36, 1422–1428 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Z. Ye, S.J. Sharp, S. Burgess, R.A. Scott, F. Imamura; InterAct Consortium, C. Langenberg, N.J. Wareham, N.G. Forouhi, Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    K.S. Vimaleswaran, D.J. Berry, C. Lu, E. Tikkanen, S. Pilz, L.T. Hiraki, J.D. Cooper, Z. Dastani, R. Li, D.K. Houston, A.R. Wood, K. Michaëlsson, L. Vandenput, L. Zgaga, L.M. Yerges-Armstrong, M.I. McCarthy, J. Dupuis, M. Kaakinen, M.E. Kleber, K. Jameson, N. Arden, O. Raitakari, J. Viikari, K.K. Lohman, L. Ferrucci, H. Melhus, E. Ingelsson, L. Byberg, L. Lind, M. Lorentzon, V. Salomaa, H. Campbell, M. Dunlop, B.D. Mitchell, K.H. Herzig, A. Pouta, A.L. Hartikainen; Genetic Investigation of Anthropometric Traits-GIANT Consortium, E.A. Streeten, E. Theodoratou, A. Jula, N.J. Wareham, C. Ohlsson, T.M. Frayling, S.B. Kritchevsky, T.D. Spector, J.B. Richards, T. Lehtimäki, W.H. Ouwehand, P. Kraft, C. Cooper, W. März, C. Power, R.J. Loos, T.J. Wang, M.R. Järvelin, J.C. Whittaker, A.D. Hingorani, E. Hyppönen, Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 10(2), e1001383 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    P.D. Chandler, L. Wang, X. Zhang, H.D. Sesso, M.V. Moorthy, O. Obi, J. Lewis, R.L. Prince, J.S. Danik, J.E. Manson, M.S. LeBoff, Y. Song, Effect of vitamin D supplementation alone or with calcium on adiposity measures: a systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 73, 577–593 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    J.C. Seida, J. Mitri, I.N. Colmers, S.R. Majumdar, M.B. Davidson, A.L. Edwards, D.A. Hanley, A.G. Pittas, L. Tjosvold, J.A. Johnson, Clinical review: effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 99, 3551–3560 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    C. Gagnon, R.M. Daly, A. Carpentier, Z.X. Lu, C. Shore-Lorenti, K. Sikaris, S. Jean, P.R. Ebeling, Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial. PLoS One 9(10), e109607 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    D.M. Mitchell, B.Z. Leder, E. Cagliero, N. Mendoza, M.P. Henao, D.L. Hayden, J.S. Finkelstein, S.A. Burnett-Bowie, Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Am. J. Clin. Nutr. 102, 385–392 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    R. Jorde, S.T. Sollid, J. Svartberg, H. Schirmer, R.M. Joakimsen, I. Njølstad, O.M. Fuskevåg, Y. Figenschau, M.Y. Hutchinson, Vitamin D 20,000 IU per week for five years does not prevent progression from prediabetes to diabetes. J. Clin. Endocrinol. Metab. 101, 1647–1655 (2016)PubMedCrossRefGoogle Scholar
  85. 85.
    A.G. Pittas, B. Dawson-Hughes, P.R. Sheehan, C.J. Rosen, J.H. Ware, W.C. Knowler, M.A. Staten; D2d Research Group., Rationale and design of the vitamin D and type 2 diabetes (D2d) study: a diabetes prevention trial. Diabetes Care 37, 3227–3234 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    L. Adorini, G. Penna, Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4, 404–412 (2008)PubMedCrossRefGoogle Scholar
  87. 87.
    M. Cutolo, Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann. Rheum. Dis. 72(4), 473–475 (2013)PubMedCrossRefGoogle Scholar
  88. 88.
    Y. Rosen, J. Daich, I. Soliman, E. Brathwaite, Y. Shoenfeld, Vitamin D and autoimmunity. Scand. J. Rheumatol. 45, 439–447 (2016)PubMedCrossRefGoogle Scholar
  89. 89.
    A.L. Ponsonby, R.M. Lucas, I.A. van der Mei, UVR, vitamin D and three autoimmune diseases-multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem. Photobiol. 81, 1267–1275 (2005)PubMedCrossRefGoogle Scholar
  90. 90.
    S.B. Mohr, C.F. Garland, E.D. Gorham, F.C. Garland, The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1diabetes in 51 regions worldwide. Diabetologia 51, 1391–1398 (2008)PubMedCrossRefGoogle Scholar
  91. 91.
    M. Cutolo, Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat. Rev. Rheumatol. 7, 500–502 (2011)PubMedCrossRefGoogle Scholar
  92. 92.
    X.C. Dopico, M. Evangelou, R.C. Ferreira, H. Guo, M.L. Pekalski, D.J. Smyth, N. Cooper, O.S. Burren, A.J. Fulford, B.J. Hennig, A.M. Prentice, A.G. Ziegler, E. Bonifacio, C. Wallace, J.A. Todd, Widespread seasonal gene expression reveals annual differences in human immunity and physiology. Nat. Commun. 6, 7000 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    B.R. Becklund, K.S. Severson, S.V. Vang, H.F. DeLuca, UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl Acad. Sci. USA 107, 6418–6423 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    R. Wei, S. Christakos, Mechanisms underlying the regulation of innate and adaptive immunity by Vitamin D. Nutrients 7, 8251–8560 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    B. Villaggio, S. Soldano, M. Cutolo, 1,25-Dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin. Exp. Rheumatol. 30, 934–938 (2012)PubMedGoogle Scholar
  96. 96.
    Y. Wang, S.J. Marling, J.G. Zhu, K.S. Severson, H.F. DeLuca, Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor. Proc. Natl Acad. Sci. USA 109, 8501–8504 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    G.B. Ferreira, C.A. Gysemans, J. Demengeot, J.P. da Cunha, A.S. Vanherwegen, L. Overbergh, T.L. Van Belle, F. Pauwels, A. Verstuyf, H. Korf, C. Mathieu, 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J. Immunol. 192, 4210–4220 (2014)PubMedCrossRefGoogle Scholar
  98. 98.
    T. Skaaby, L. Husemoen, B. Thuesen, A. Linneberg, Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease. Endocrine 50, 231–238 (2015)PubMedCrossRefGoogle Scholar
  99. 99.
    S. Duan, Z. Lv, X. Fan, L. Wang, F. Han, H. Wang, S. Bi, Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci. Lett. 570, 108–113 (2014)PubMedCrossRefGoogle Scholar
  100. 100.
    L.E. Mokry, S. Ross, O.S. Ahmad, V. Forgetta, G.D. Smith, D. Goltzman, A. Leong, C.M. Greenwood, G. Thanassoulis, J.B. Richards, Vitamin D and risk of multiple sclerosis: a mendelian randomization study. PLoS Med. 12(8), e1001866 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    B. Rhead, M. Bäärnhielm, M. Gianfrancesco, A. Mok, X. Shao, H. Quach, L. Shen, C. Schaefer, J. Link, A. Gyllenberg, A.K. Hedström, T. Olsson, J. Hillert, I. Kockum, M.M. Glymour, L. Alfredsson, L.F. Barcellos, Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol. Genet 2(5), e97 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    A. Ascherio, K.L. Munger, R. White, K. Köchert, K.C. Simon, C.H. Polman, M.S. Freedman, H.P. Hartung, D.H. Miller, X. Montalbán, G. Edan, F. Barkhof, D. Pleimes, E.W. Radü, R. Sandbrink, L. Kappos, C. Pohl, Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 71, 306–314 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    K.C. Fitzgerald, K.L. Munger, K. Köchert, B.G. Arnason, G. Comi, S. Cook, D.S. Goodin, M. Filippi, H.P. Hartung, D.R. Jeffery, P. O’Connor, G. Suarez, R. Sandbrink, L. Kappos, C. Pohl, A. Ascherio, Association of Vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon Beta-1b. JAMA Neurol 72, 1458–1465 (2015)PubMedCrossRefGoogle Scholar
  104. 104.
    N. Stewart, S. Simpson Jr, I. van der Mei, A.L. Ponsonby, L. Blizzard, T. Dwyer, F. Pittas, D. Eyles, P. Ko, B.V. Taylor, Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 79, 254–260 (2012)PubMedCrossRefGoogle Scholar
  105. 105.
    G. Bock, B. Prietl, J.K. Mader, E. Höller, M. Wolf, S. Pilz, W.B. Graninger, B.M. Obermayer-Pietsch, T.R. Pieber, The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes .Metab. Res. Rev. 27, 942–945 (2011)PubMedCrossRefGoogle Scholar
  106. 106.
    G.G. Konijeti, P. Arora, M.R. Boylan, Y. Song, S. Huang, F. Harrell, C. Newton-Cheh, D. O’Neill, J. Korzenik, T.J. Wang, A.T. Chan, Vitamin D supplementation modulates T cell-mediated immunity in humans: results from a randomized control trial. J. Clin. Endocrinol. Metab. 101, 533–538 (2016)PubMedCrossRefGoogle Scholar
  107. 107.
    F. Ashtari, N. Toghianifar, S.H. Zarkesh-Esfahani, M. Mansourian, High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: arandomized, double-blind, placebo-controlled clinical trial. Neurol. Res. 38, 888–892 (2016)PubMedCrossRefGoogle Scholar
  108. 108.
    E.S. Sotirchos, P. Bhargava, C. Eckstein, K. Van Haren, M. Baynes, A. Ntranos, A. Gocke, L. Steinman, E.M. Mowry, P.A. Calabresi, Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 86, 382–390 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    B. Pozuelo-Moyano, J. Benito-León, A.J. Mitchell, J. Hernández-Gallego, A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 40, 147–153 (2013)PubMedCrossRefGoogle Scholar
  110. 110.
    E. Hyppönen, E. Läärä, A. Reunanen, M.R. Järvelin, S.M. Virtanen, Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358, 1500–1503 (2001)PubMedCrossRefGoogle Scholar
  111. 111.
    T. Takiishi, L. Ding, F. Baeke, I. Spagnuolo, G. Sebastiani, J. Laureys, A. Verstuyf, G. Carmeliet, F. Dotta, T.L. Van Belle, C.A. Gysemans, C. Mathieu, Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes 63, 2026–2036 (2014)PubMedCrossRefGoogle Scholar
  112. 112.
    X. Li, L. Liao, X. Yan, G. Huang, J. Lin, M. Lei, X. Wang, Z. Zhou, Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 25, 411–416 (2009)PubMedCrossRefGoogle Scholar
  113. 113.
    G. Treiber, B. Prietl, E. Fröhlich-Reiterer, E. Lechner, A. Ribitsch, M. Fritsch, B. Rami-Merhar, C. Steigleder-Schweiger, W. Graninger, M. Borkenstein, T.R. Pieber, Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus—a randomized clinical trial. Clin. Immunol. 161, 217–224 (2015)PubMedCrossRefGoogle Scholar
  114. 114.
    M. Cutolo, K. Otsa, K. Laas, M. Yprus, R. Lehtme, M.E. Secchi, A. Sulli, S. Paolino, B. Seriolo, Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 24, 702–704 (2006)PubMedGoogle Scholar
  115. 115.
    M. Cutolo, C. Pizzorni, A. Sulli, Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun. Rev. 11, 84–87 (2011)PubMedCrossRefGoogle Scholar
  116. 116.
    D.J. Birmingham, L.A. Hebert, H. Song, W.T. Noonan, B.H. Rovin, H.N. Nagaraja, C.Y. Yu, Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 21, 855–864 (2012)PubMedCrossRefGoogle Scholar
  117. 117.
    M. Racovan, B. Walitt, C.E. Collins, M. Pettinger, C.G. Parks, J.M. Shikany, J. Wactawski-Wende, J.E. Manson, L. Moreland, N. Wright, R. Jackson, B.V. Howard, Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women’s Health initiative calcium plus Vitamin D trial. Rheumatol. Int. 32, 3823–3830 (2012)PubMedCrossRefGoogle Scholar
  118. 118.
    K.H. Costenbader, D. Feskanich, M. Holmes, E.W. Karlson, E. Benito-Garcia, Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 67, 530–535 (2008)PubMedCrossRefGoogle Scholar
  119. 119.
    G.G. Song, S.C. Bae, Y.H. Lee, Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin. Rheumatol. 31, 1733–1739 (2012)PubMedCrossRefGoogle Scholar
  120. 120.
    J. Lin, J. Liu, M.L. Davies, W. Chen, Serum Vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One 11(1), e0146351 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    A. Abou-Raya, S. Abou-Raya, M. Helmii, The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J. Rheumatol. 40, 265–272 (2013)PubMedCrossRefGoogle Scholar
  122. 122.
    S. Piantoni, L. Andreoli, M. Scarsi, A. Zanola, F. Dall’Ara, C. Pizzorni, M. Cutolo, P. Airò, A. Tincani, Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. Lupus 24, 490–498 (2015)PubMedCrossRefGoogle Scholar
  123. 123.
    L. Andreoli, F. Dall’Ara, S. Piantoni, A. Zanola, N. Piva, M. Cutolo, A. Tincani, A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. Lupus 24(4-5), 499–506 (2015)PubMedCrossRefGoogle Scholar
  124. 124.
    S. Straube, S. Derry, C. Straube, R.A. Moore, Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst. Rev. (5):CD007771. doi: 10.1002/14651858.CD007771.pub3 (2015)
  125. 125.
    J.C. Fleet, M. DeSmet, R. Johnson, Y. Li, Vitamin D and cancer: a review of molecular mechanisms. Biochem. J. 441, 61–76 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    D.D. Bikle, Y. Jiang, T. Nguyen, Y. Oda, C.L. Tu, Disruption of vitamin D and calcium signaling in keratinocytes predisposes to skin cancer. Front. Physiol 7, 296 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Y. Zheng, H. Zhou, L.L. Ooi, A.D. Snir, C.R. Dunstan, M.J. Seibel, Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 71(9), 1012–1021 (2011)PubMedCrossRefGoogle Scholar
  128. 128.
    D. Santini, F. Pantano, B. Vincenzi, G. Tonini, F. Bertoldo, The role of bone microenvironment, vitamin D and calcium. Recent Results Cancer Res. 192, 33–64 (2012)PubMedCrossRefGoogle Scholar
  129. 129.
    C.F. Garland, F.C. Garland, E.D. Gorham, M. Lipkin, H. Newmark, S.B. Mohr, M.F. Holick, The role of vitamin D in cancer prevention. Am. J. Public Health 96, 252–261 (2006)PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    E. Giovannucci, The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16, 83–95 (2005)PubMedCrossRefGoogle Scholar
  131. 131.
    K.D. Crew, E. Shane, S. Cremers, D.J. McMahon, D. Irani, D.L. Hershman, High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J. Clin. Oncol. 27, 2151–2156 (2009)PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    H. Li, M.J. Stampfer, J.B. Hollis, L.A. Mucci, J.M. Gaziano, D. Hunter, E.L. Giovannucci, J. Ma, A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 4(3), e103 (2007)PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    T.C. Chen, A. Kittaka Novel vitamin D analogs for prostate cancer therapy. ISRN Urol. 2011:301490 (2011)Google Scholar
  134. 134.
    C.F. Garland, E.D. Gorham, S.B. Mohr, F.C. Garland, Vitamin D for cancer prevention: global perspective. Ann. Epidemiol. 19, 468–483 (2009)PubMedCrossRefGoogle Scholar
  135. 135.
    M. Waterhouse, H.A. Risch, C. Bosetti, K.E. Anderson, G.M. Petersen, W.R. Bamlet, M. Cotterchio, S.P. Cleary, T.I. Ibiebele, C. La Vecchia, H.G. Skinner, L. Strayer, P.M. Bracci, P. Maisonneuve, H.B. Bueno-de-Mesquita, W. Zatoński, L. Lu, H. Yu, K. Janik-Koncewicz, J. Polesel, D. Serraino, R.E. Neale; Pancreatic Cancer Case–Control Consortium (PanC4)., Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic cancer case–control consortium. Ann. Oncol. 27, 208 (2016)PubMedCrossRefGoogle Scholar
  136. 136.
    M.J. Mun, T.H. Kim, J.Y. Hwang, W.C. Jang, Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: a meta-analysis. Maturitas 81, 256–265 (2015)PubMedCrossRefGoogle Scholar
  137. 137.
    E. Tagliabue, S. Raimondi, S. Gandini, Meta-analysis of vitamin D-binding protein and cancer risk. Cancer Epidemiol. Biomark. Prev. 24, 1758–1765 (2015)CrossRefGoogle Scholar
  138. 138.
    J.E. Manson, S.T. Mayne, S.K. Clinton, Vitamin D and prevention of cancer-ready for prime time? N. Engl. J. Med. 364, 1385–1387 (2011)PubMedCrossRefGoogle Scholar
  139. 139.
    J.M. Lappe, D. Travers-Gustafson, K.M. Davies, R.R. Recker, R.P. Heaney, Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 85, 1586–1591 (2007)PubMedGoogle Scholar
  140. 140.
    M. Chung, J. Lee, T. Terasawa, J. Lau, T.A. Trikalinos, Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 827–838 (2011)PubMedCrossRefGoogle Scholar
  141. 141.
    G. Bjelakovic, L.L. Gluud, D. Nikolova, K. Whitfield, G. Krstic, J. Wetterslev, C. Gluud, Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst. Rev. (6):CD007469. doi: 10.1002/14651858.CD007469.pub2 (2014)
  142. 142.
    J.A. Baron, E.L. Barry, L.A. Mott, J.R. Rees, R.S. Sandler, D.C. Snover, R.M. Bostick, A. Ivanova, B.F. Cole, D.J. Ahnen, G.J. Beck, R.S. Bresalier, C.A. Burke, T.R. Church, M. Cruz-Correa, J.C. Figueiredo, M. Goodman, A.S. Kim, D.J. Robertson, R. Rothstein, A. Shaukat, M.E. Seabrook, R.W. Summers, A trial of calcium and vitamin D for the prevention of colorectal adenomas. N. Engl. J. Med. 373, 1519–1530 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    N. Keum, E. Giovannucci, Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br. J. Cancer 111, 976–980 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    M. Jeffreys, M.T. Redaniel, R.M. Martin, The effect of pre-diagnostic vitamin D supplementation on cancer survival in women: a cohort study within the UK clinical practice research datalink. BMC Cancer 15, 670 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    M. Ben-Eltriki, S. Deb, E.S. Guns, Calcitriol in combination therapy for prostate cancer: pharmacokinetic and pharmacodynamic interactions. J. Cancer 7, 391–407 (2016)PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    A. Berruti, R. Cook, F. Saad, C. Buttigliero, A. Lipton, M. Tampellini, K.A. Lee, R.E. Coleman, M.R. Smith, Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 17, 645–652 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, B. Chen; Zoledronic Acid Prostate Cancer Study Group., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer. Inst. 94, 1458–1468 (2002)PubMedCrossRefGoogle Scholar
  148. 148.
    R. Rizzoli, J.J. Body, M.L. Brandi, J. Cannata-Andia, D. Chappard, A. El Maghraoui, C.C. Glüer, D. Kendler, N. Napoli, A. Papaioannou, D.D. Pierroz, M. Rahme, C.H. Van Poznak, T.J. de Villiers, G. El Hajj Fuleihan; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease., Cancer-associated bone disease. Osteoporos. Int. 24, 2929–2953 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    D.J. Berry, K.S. Vimaleswaran, J.C. Whittaker, A.D. Hingorani, E. Hyppönen, Evaluation of genetic markers as instruments for Mendelian randomization studies on vitamin D. PLoS One 7(5), e37465 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    K.M. Sanders, A.L. Stuart, E.J. Williamson, J.A. Simpson, M.A. Kotowicz, D. Young, G.C. Nicholson, Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303, 1815–1822 (2010)PubMedCrossRefGoogle Scholar
  151. 151.
    A.T. Slominski, T.K. Kim, J.V. Hobrath, A.S. Oak, E.K. Tang, E.W. Tieu, W. Li, R.C. Tuckey, A.M. Jetten, Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem. Mol. Biol. pii: S0960-0760(16)30260-6. doi: 10.1016/j.jsbmb.2016.09.024. [Epub ahead of print] (2016)
  152. 152.
    J.C. Gallagher, Vitamin D and falls—the dosage conundrum. Nat. Rev. Endocrinol 12, 680–684 (2016)PubMedCrossRefGoogle Scholar
  153. 153.
    M. Herrmann, C.L. Farrell, I. Pusceddu, N. Fabregat-Cabello, E. Cavalier, Assessment of vitamin D status—a changing landscape. Clin. Chem. Lab. Med. 55, 3–26 (2017)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Luisella Cianferotti
    • 1
  • Francesco Bertoldo
    • 2
  • Heike A. Bischoff-Ferrari
    • 3
  • Olivier Bruyere
    • 4
  • Cyrus Cooper
    • 5
  • Maurizio Cutolo
    • 6
  • John A. Kanis
    • 7
    • 8
  • Jean-Marc Kaufman
    • 9
  • Jean-Yves Reginster
    • 10
  • Rene Rizzoli
    • 11
  • Maria Luisa Brandi
    • 1
    Email author
  1. 1.Bone Metabolic Diseases Unit, Department of Surgery and Translational MedicineUniversity Hospital of Florence and University of FlorenceFlorenceItaly
  2. 2.Department of MedicineUniversity of VeronaVeronaItaly
  3. 3.Department of Geriatrics and Aging ResearchUniversity Hospital Zurich and University of ZurichZurichSwitzerland
  4. 4.Epidemiology and Public HealthUniversity of Liege, CHU Sart TilmanLiegeBelgium
  5. 5.MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK
  6. 6.Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal MedicineUniversity of GenovaGenoaItaly
  7. 7.Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  8. 8.Institute for Health and AgingCatholic University of AustraliaMelbourneAustralia
  9. 9.Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone DiseasesGhent University HospitalGhentBelgium
  10. 10.Department of Public Health, Epidemiology and Health EconomicsUniversity of Liège, CHU Sart-TilmanLiègeBelgium
  11. 11.Service of Bone DiseasesGeneva University Hospitals and Faculty of MedicineGenevaSwitzerland

Personalised recommendations